NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

LogicBio Therapeutics Inc (F: 0IF)

 
0IF Technical Analysis
4
As on 15th Nov 2022 0IF STOCK Price closed @ 2.04 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2.63 & Strong Sell for SHORT-TERM with Stoploss of 3.56 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

0IFSTOCK Price

Open 2.04 Change Price %
High 2.04 1 Day 0.00 0.00
Low 2.04 1 Week -0.04 -1.92
Close 2.04 1 Month 1.75 603.45
Volume N/A 1 Year -1.56 -43.33
52 Week High 4.26 | 52 Week Low 0.28
 
F Germany Most Active Stocks
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
JYR 1000000.00 10000000000.00%
JYR 1000000.00 10000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
HGF2 7.40 1380.00%
 
F Germany Top Losers Stocks
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
LDB 1.71 -92.57%
 
 
0IF
Daily Charts
0IF
Intraday Charts
Whats New @
Bazaartrend
0IF
Free Analysis
 
0IF Important Levels Intraday
RESISTANCE2.04
RESISTANCE2.04
RESISTANCE2.04
RESISTANCE2.04
RESISTANCE2.04
RESISTANCE2.04
RESISTANCE2.04
RESISTANCE2.04
 
0IF Forecast December 2024
4th UP Forecast3
3rd UP Forecast2.69
2nd UP Forecast2.5
1st UP Forecast2.31
1st DOWN Forecast1.77
2nd DOWN Forecast1.58
3rd DOWN Forecast1.39
4th DOWN Forecast1.08
 
0IF Weekly Forecast
4th UP Forecast2.81
3rd UP Forecast2.56
2nd UP Forecast2.41
1st UP Forecast2.26
1st DOWN Forecast1.82
2nd DOWN Forecast1.67
3rd DOWN Forecast1.52
4th DOWN Forecast1.27
 
0IF Forecast2024
4th UP Forecast9.79
3rd UP Forecast7.3
2nd UP Forecast5.77
1st UP Forecast4.23
1st DOWN Forecast-0.15
2nd DOWN Forecast-1.69
3rd DOWN Forecast-3.22
4th DOWN Forecast-5.71
 
 
0IF Other Details
Segment EQ
Market Capital 100866608.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
0IF Address
0IF
 
0IF Latest News
 
Your Comments and Response on LogicBio Therapeutics Inc
 
0IF Business Profile
LogicBio Therapeutics, Inc., a genome editing company, focuses on developing medicines to treat rare diseases in patients with unmet medical need using GeneRide technology platform. The GeneRide technology is designed to integrate corrective genes into a patient's genome to provide a therapeutic effect. The company's lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. It has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as two additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop next-generation capsids for gene therapy and editing candidate LB-301 for the treatment of crigler-najjar syndrome. The company also has a strategic collaboration and option agreement with CANbridge Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Address: 65 Hayden Avenue, Lexington, MA, United States, 02421
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service